Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Cancer Research

METTL14 Enhances Anti-Tumor Immunity through m6A-dependent loss of PD-1

View Full Paper
Ask AI
Bookmark
Share

Authors

CHChang HuangXWXiaodong WangYGYinmin Gu

Discussion

Loading...

Member takes

Overview

Analysis reveals METTL14's impact on PD-1 regulation in T cells, suggesting novel immunotherapy strategies.

Key Points

  • The loss of PD-1 through m6A modification enhances anti-tumor immunity.
  • Heterozygous METTL14 deficiency elevated PD-1 levels and impaired CD8+ T cell activation.
  • The study identifies a significant link between METTL14 and PDCD1 levels across multiple cancer types.
  • Combining WD6305 with anti-PD-1 therapy demonstrates potential for improved tumor treatment outcomes.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68c2384fb210217d64776b57https://doi.org/10.1158/0008-5472.can-25-0065
View Full Paper
Ask AI
Bookmark
Share